| Females, n (%) |
15 (83.3) |
5 (55.6) |
|
| Males, n (%) |
3 (16.7) |
4 (44.4) |
|
| Age, y (median) |
51.5 (28–63) |
45 (27–68) |
|
| Smokers, n (%) |
8 (44.4) |
2 (22.2) |
|
| Duration GD, month (median) |
8.5 (3–40) |
18 (7–42) |
0.047 |
| TRAb, lU/L (reference range, <1.8) |
5.4 (0.9–30.0) |
<0.9 (<0.9–4.7) |
0.003 |
| Radioiodine treatment, n (%) |
1 (5.5) |
0 (0) |
0.48 |
| Thyroid surgery, n (%) |
2 (11.1) |
0 (0) |
0.31 |
| TSH, mlU/L (median; reference range, 0.5–3.6) |
0.04 (0.03–1.7) |
0.1 (0.03–2.33) |
0.65 |
| Serum FT4, pmol/L (reference range, 8–21) |
21.3 (12.2–28.2) |
18.6 (11.4–26.1) |
0.37 |
| Serum FT3, pmol/L (reference range, 3.6–8.3) |
6.3 (4.6–11.7) |
6.2 (4.8–8.6) |
0.93 |
